{"id":"https://genegraph.clinicalgenome.org/r/a0a9ec11-ef90-4095-9c9e-696eabd0395bv2.1","type":"EvidenceStrengthAssertion","dc:description":["*GDI1* was first reported in relation to non-syndromic X-linked intellectual disability in 1996 (Hamel et al., PMID: 8826463). Frequently reported phenotypic features in males include intellectual disability varying from mild to severe. Female carriers range from mild intellectual disability to intellect in the normal range. Five variants (missense, protein truncating, and frameshift) that have been reported in five probands in six publications (PMIDs: 8826463, 9106537, 9620768, 9668174, 22002931, and 28863211) are included in this curation. For four of the reported probands, segregation scoring was included based on published LOD scores within the appropriate articles. The mechanism of pathogenicity is most likely loss of function.\n\nThe gene-disease relationship is also supported by animal models and functional alteration data (PMIDs: 9620768, 20159109, 22291894, and 10473636). *GDI1* knockout mouse models showed behavioral features consistent with neurodevelopmental disorders such as impaired short term memory, altered social behavior, cognitive impairment in mazes, and impaired attention (PMID: 9620768). Rat-derived neurons treated with *GDI1* knockdown antisense oligonucleotides had reduced growth and function, suggesting *GDI1* plays an important role in neurodevelopment (PMIDs: 9620768 and 10473636).\n\nThis gene-disease pair was originally evaluated by the Intellectual Disability and Autism Gene Curation Expert Panel on May 24, 2018 (SOP Version 5). It was reevaluated on April 27, 2023 (SOP Version 10). As a result of this reevaluation, the classification did not change. This gene-disease pair remains classified as moderate due to limited reported variants. Additionally, the reported phenotypes have been nonspecific and testing has been targeted to X-linked genes rather than comprehensive exome or genome sequencing.\n","*GDI1* was first reported in relation to non-syndromic X-linked intellectual disability in 1996 (Hamel et al., PMID: 8826463). Frequently reported phenotypic features in males include intellectual disability varying from mild to severe. Female carriers range from mild intellectual disability to intellect in the normal range. Five variants (missense, protein truncating, and frameshift) that have been reported in five probands in six publications (PMIDs: 8826463, 9620768, 9106537, 9668174, 22002931, and 28863211) are included in this curation. For four of the reported probands, segregation scoring was included based on published LOD scores within the appropriate articles. \n\nThe mechanism of pathogenicity is most likely loss of function. The gene-disease relationship is also supported by animal models and functional alteration data (PMIDs: 9620768, 20159109, 22291894, and 10473636). *GDI1* knockout mouse models showed behavioral features consistent with neurodevelopmental disorders such as impaired short term memory, altered social behavior, cognitive impairment in mazes, and impaired attention (PMID: 9620768). Rat-derived neurons treated with *GDI1* knockdown antisense oligonucleotides had reduced growth and function, suggesting *GDI1* plays an important role in neurodevelopment (PMIDs: 9620768 and 10473636).\n\nThis gene-disease pair was originally evaluated by the Intellectual Disability and Autism GCEP on May 24, 2018 (SOP Version 5) . It was reevaluated on April 27, 2023 (SOP Version 10). As a result of this reevaluation, the classification did not change. This gene-disease pair remains classified as moderate due to limited reported variants. Additionally, the reported phenotypes have been nonspecific and testing has been targeted to X-linked genes rather than comprehensive exome or genome sequencing.\n"],"dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/a0a9ec11-ef90-4095-9c9e-696eabd0395b","GCISnapshot":"https://genegraph.clinicalgenome.org/r/8afc42b0-6c5e-460b-87d1-035c051fe7ca","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/8afc42b0-6c5e-460b-87d1-035c051fe7ca_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2025-08-04T13:27:39.754Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/8afc42b0-6c5e-460b-87d1-035c051fe7ca_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":["2023-04-26T22:00:00.000Z","2023-04-27T06:00:00.000Z"],"role":"Approver"}],"curationReasonDescription":"Downgraded for probands having a nonspecific phenotype and for limited assessment of other causes of disease. ","curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8afc42b0-6c5e-460b-87d1-035c051fe7ca_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8afc42b0-6c5e-460b-87d1-035c051fe7ca_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e603d43-5f6f-4a8e-8c69-2324a5e78176","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4691f380-6f9c-46d0-8ac4-97882cc974e9","type":"FunctionalAlteration","dc:description":"trk-PC12 cells treated with GDI1 antisense oligonucelotides had decreased neurite extension.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10473636","rdfs:label":"Neurite extension Leoni"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/eb6412d9-ddab-42d6-972f-9c9fc0dd6faa","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e965252c-86d9-492f-9f65-c2171638b368","type":"FunctionalAlteration","dc:description":"Variants were found in RAB39B associated with XLID.  GDI1 interacts with RAB39B.  Per Bianchi et al. 2012, this \"supports the importance of the intracellular trafficking mediated by the aGDI-RAB GTPase pathway in the development of cognitive function.\"","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20159109","rdfs:label":"Giannandrea 2010 Protein Interaction"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0cba6aac-e977-49e4-bdd8-e3647f0df7fb","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/835c8dec-2d5b-4fd2-a96e-7911b8f5d2a0","type":"FunctionalAlteration","dc:description":"Using electron microscopy and electrophysiology, we now report that lack of aGDI impairs several steps in synaptic vesicle (SV) biogenesis and recycling in the hippocampus","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22291894","rdfs:label":"Bianchi - Functional Alteration Non-Patient Cells"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/8afc42b0-6c5e-460b-87d1-035c051fe7ca_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/afafc2e1-d56b-4a5d-979b-9387bd99d844","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5d2d55b4-230f-4216-9fa6-7ea136b6decd","type":"Finding","dc:description":"Using electron microscopy and electrophysiology, we now report that lack of aGDI impairs several steps in synaptic vesicle (SV) biogenesis and recycling in the hippocampus","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22291894","rdfs:label":"Bianchi - Model and Rescue","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/deed97dd-4578-43eb-a3ce-da52894a2871","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5eba6a8b-c25d-45af-98c8-da8c414c4e97","type":"Finding","dc:description":"In mice, as in humans, lack of Gdi1 spares most central nervous system functions and preferentially impairs only a few forebrain functions required to form temporal associations.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620768","rdfs:label":"D'Adamo Models and Rescue - Animal Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5.5},{"id":"https://genegraph.clinicalgenome.org/r/8afc42b0-6c5e-460b-87d1-035c051fe7ca_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dd79d3ee-7c6d-4539-8da6-14b2da391a9c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dd79d3ee-7c6d-4539-8da6-14b2da391a9c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620768","allele":{"id":"https://genegraph.clinicalgenome.org/r/895f3f67-c732-43d6-a57b-e162d54f02b4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001493.3(GDI1):c.275T>C (p.Leu92Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11626"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/dd79d3ee-7c6d-4539-8da6-14b2da391a9c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant expressed in E. coli showed reduced ability to bind RAB3A.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/23ee3af1-ac4e-42fd-b756-79ec36dee819","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/23ee3af1-ac4e-42fd-b756-79ec36dee819_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620768","allele":{"id":"https://genegraph.clinicalgenome.org/r/44ff3d70-66a7-471e-8390-eea2ad4fca6a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001493.3(GDI1):c.208C>T (p.Arg70Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11627"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/23ee3af1-ac4e-42fd-b756-79ec36dee819_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Western blot shows no GDI1 protein expression in affected patient.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/c32b5768-9709-44e7-ada4-f835921e384b","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c32b5768-9709-44e7-ada4-f835921e384b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9668174","allele":{"id":"https://genegraph.clinicalgenome.org/r/a7749a18-8ea4-4254-9685-97f129ee0823","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001493.3(GDI1):c.1268G>C (p.Arg423Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11628"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/8afc42b0-6c5e-460b-87d1-035c051fe7ca_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0087c979-8cb6-4959-bc64-07a48a61983b_family_segregation","type":"FamilyCosegregation","dc:description":"Sequenced more than 1 gene on the X, higher than just candidate gene sequencing","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22002931","rdfs:label":"Strobl-Wildemann - Segregation Scoring","family":{"id":"https://genegraph.clinicalgenome.org/r/0087c979-8cb6-4959-bc64-07a48a61983b","type":"Family","rdfs:label":"Strobl-Wildemann - Segregation Scoring"},"meetsInclusionCriteria":true,"phenotype":{"id":"obo:HP_0001249"},"phenotypePositiveAllelePositive":8,"publishedLodScore":2.41,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/252efc2a-f737-4fca-b4fd-2c77308c7e14_family_segregation","type":"FamilyCosegregation","dc:description":"LOD = 3.3 (author-calculated). GDI1 pathogenic variant specifically associated with disease in this family in D'Adamo et al., 1998. Western Blot shows no GDI1 protein expression in affected pt. - Information is from D'Adamo paper already counted","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9106537","rdfs:label":"Des Portes Family 1","family":{"id":"https://genegraph.clinicalgenome.org/r/252efc2a-f737-4fca-b4fd-2c77308c7e14","type":"Family","rdfs:label":"Des Portes Family 1"},"meetsInclusionCriteria":false,"phenotype":{"id":"obo:HP_0001249"},"phenotypeFreeText":"Mental retardation, mild to severe","phenotypePositiveAllelePositive":9,"publishedLodScore":3.3},{"id":"https://genegraph.clinicalgenome.org/r/7308c709-d2a0-4c63-a0a6-f5415b6e16f8_family_segregation","type":"FamilyCosegregation","dc:description":"D'Adamo et al. state that \"affected and nonaffected relatives and obligate carriers were analysed and the mutations were shown to segregate with the disease,\" but they do not specify which individuals were actually tested. The number of affected individuals in the pedigree in Hamel et al. is 8, with at least 3 obligate carriers. Hamel et al. (PMID:8826463) performed \"[t]wo point linkage analysis demonstrat[ing] linkage between the disorder and marker DXS3 in Xq21.33 with a lod score of 2.56 at theta = 0.0 and marker DXSllO8 in Xq28 with a lod score of 3.82 at theta = 0.0.\" Using the estimated LOD score calculation and assuming all affected individuals and obligate carriers were tested and found to carry the variant, the estimated LOD score could be up to 3. Opting to use the more conservative LOD score published in Hamel due to the ambiguity of the information published in this paper (D'Adamo et al. 1998).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620768","rdfs:label":"D'Adamo 1998 Family MRX41 - Segregation Scoring","family":{"id":"https://genegraph.clinicalgenome.org/r/7308c709-d2a0-4c63-a0a6-f5415b6e16f8","type":"Family","rdfs:label":"D'Adamo 1998 Family MRX41 - Segregation Scoring"},"meetsInclusionCriteria":true,"phenotype":{"id":"obo:HP_0001249"},"phenotypeFreeText":"This family is described in Hamel et al. 1996 (PMID:8826463); a pedigree can be found in this publication. Intellectual disability (ID) was mild-moderate, non-progressive and evident in the first years of life. Per the authors of that study: \"None of the affected males is institutionalized, but all attended special schools for children with (severe) learning problems. They all live and work in a sheltered environment. There was no consistent clinical phenotype other than the mental retardation. Obvious neurological symptoms and signs were not present. Height, weight, and OFC were all within normal limits. Their behaviour is unremarkable.\" All obligate and possible carriers were said to be of normal intelligence.","phenotypePositiveAllelePositive":8,"publishedLodScore":2.56,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/3fc324ee-db90-407a-b8ae-c77e8040bfe6_family_segregation","type":"FamilyCosegregation","dc:description":"LOD = 3.82 (author-calculated).  Disease named MRX41.  GDI1 pathogenic variant specifically associated with disease in this family in D'Adamo et al., 1998. Mutant GDI1 expressed in E. coli demonstrated reduced ability compared with WT GDI1 to bind RAB3A in vitro .","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8826463","rdfs:label":"Hamel 1996 MRX41 Family","family":{"id":"https://genegraph.clinicalgenome.org/r/3fc324ee-db90-407a-b8ae-c77e8040bfe6","type":"Family","rdfs:label":"Hamel 1996 MRX41 Family"},"meetsInclusionCriteria":false,"phenotype":{"id":"obo:HP_0001249"},"phenotypeFreeText":"Intellectual disability, mild to moderate","phenotypePositiveAllelePositive":8,"publishedLodScore":3.82},{"id":"https://genegraph.clinicalgenome.org/r/c9848e0e-5a86-4bb5-bf1a-f2e1e0b4de10_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22002931","rdfs:label":"Strobl-Wildemann Family 1","estimatedLodScore":2.41,"family":{"id":"https://genegraph.clinicalgenome.org/r/c9848e0e-5a86-4bb5-bf1a-f2e1e0b4de10","type":"Family","rdfs:label":"Strobl-Wildemann Family 1","member":{"id":"https://genegraph.clinicalgenome.org/r/0cb3b7f4-8704-47d6-a687-29bb2bbd5e2f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22002931","rdfs:label":"Strobl-Wilemann Proband 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"allele":{"id":"https://genegraph.clinicalgenome.org/r/b152381d-b705-4ef5-93ba-bfd27d966769","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001493.3(GDI1):c.1186_1187del (p.Ser396ProfsTer15)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/29933"}},"detectionMethod":"Per the authors: \"During a study to elucidate the genetic defects in families with apparent XLID, we performed enrichment of the coding and flanking intronic sequences of 86 known XLID genes followed by next-generation sequencing using the Illumina/Solexa system. Details of this approach are delineated in Hu et al. [2009].\"","phenotypeFreeText":"The proband is individual V5; his IQ was 55 at 12 years of age. \"Electroencephalography (EEG) revealed 3/sec spike wave paroxysms. An MRI scan had a normal result. Facial features included a small pointed chin and crowded teeth, but he had no major dysmorphic signs.\"","phenotypes":["obo:HP_0001763","obo:HP_0000750","obo:HP_0001263","obo:HP_0002121","obo:HP_0000486"],"previousTesting":true,"previousTestingDescription":"Conventional cytogenetic analysis, fragile-X testing and arrayCGH (Agilent 244K array) analysis had normal results.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f13b920a-fcce-4133-a04b-24d8ffafcaae_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22002931","allele":{"id":"https://genegraph.clinicalgenome.org/r/b152381d-b705-4ef5-93ba-bfd27d966769"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":9,"phenotypes":"obo:HP_0001249","proband":{"id":"https://genegraph.clinicalgenome.org/r/0cb3b7f4-8704-47d6-a687-29bb2bbd5e2f"},"publishedLodScore":2.4,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/a0535ed8-40bd-4825-94ae-f88e496f5630_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9668174","rdfs:label":"Bienvenu Family R - Segregation Scoring","family":{"id":"https://genegraph.clinicalgenome.org/r/a0535ed8-40bd-4825-94ae-f88e496f5630","type":"Family","rdfs:label":"Bienvenu Family R - Segregation Scoring"},"meetsInclusionCriteria":true,"phenotype":{"id":"obo:HP_0001249"},"phenotypeFreeText":"All affected males show moderate-severe intellectual disability (ID). No statural growth deficiency, or minor facial or other abnormal physical features were observed. Seizures present in one affected patient in the family. Proband is individual IV-7; developmental quotient 25 at age 3 years. Clinical assessment, including growth chart, hearing, vision and skin examination was normal. brain magnetic resonance imaging (MRI), electroencephalogram (EEG), biochemical blood and urine screening (thyroid-stimulating hormone, free thyroxine, amino acid chromatography) were normal. Females III-9, III-11 and III-13 have a borderline intellectual functioning or a mild mental retardation and behavioural troubles with psychiatric features and social difficulties.","phenotypePositiveAllelePositive":3,"publishedLodScore":3.01,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/52a06c8e-3f1c-4fd2-9d3e-ba33c1c6f578_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620768","rdfs:label":"D'Adamo 1998 Family MRX48","family":{"id":"https://genegraph.clinicalgenome.org/r/52a06c8e-3f1c-4fd2-9d3e-ba33c1c6f578","type":"Family","rdfs:label":"D'Adamo 1998 Family MRX48","member":{"id":"https://genegraph.clinicalgenome.org/r/24b132c6-bcfd-4b3d-b24e-44591b9e8755","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620768","rdfs:label":"D'Adamo MRX48 Proband (IV-8)","allele":{"id":"https://genegraph.clinicalgenome.org/r/44ff3d70-66a7-471e-8390-eea2ad4fca6a"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"This family is described in DesPortes et al. (1997) (PMID: 9106537).  Per the authors of that publication, \"all affected males show moderate to severe mental retardation.\"","phenotypes":"obo:HP_0001249","previousTesting":true,"previousTestingDescription":"Per DesPortes: \"In individual IV-8, several investigations were performed to rule out any known mental retardation etiology: no chromosomal rearrangement has been observed by high resolution karyotype; fragile X syndrome was ruled out by the molecular method using the StB12.3 probe on EcoRI-digested genomic DNA (Rousseau et al. 1991). Brain MRI..., skeletal radiographs, and biochemical blood and urine screening (blood-cell count, uric acid, amino acid and organic acid chromatography, and a and , mannosidase activity) were normal.\"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/23ee3af1-ac4e-42fd-b756-79ec36dee819_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"This family is described in DesPortes et al. (1997) (PMID: 9106537).  Per the authors of that publication, \"all affected males show moderate to severe mental retardation.\"","phenotypePositiveAllelePositive":8,"phenotypes":"obo:HP_0001249","proband":{"id":"https://genegraph.clinicalgenome.org/r/24b132c6-bcfd-4b3d-b24e-44591b9e8755"},"publishedLodScore":3.3,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/4192d1f3-546c-4168-a3ad-341478f4699d_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9668174","rdfs:label":"Bienvenu Family R","family":{"id":"https://genegraph.clinicalgenome.org/r/4192d1f3-546c-4168-a3ad-341478f4699d","type":"Family","rdfs:label":"Bienvenu Family R","member":{"id":"https://genegraph.clinicalgenome.org/r/b0406c48-a281-4207-984f-56121342fa27","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9668174","rdfs:label":"Bienvenu Proband R","allele":{"id":"https://genegraph.clinicalgenome.org/r/a7749a18-8ea4-4254-9685-97f129ee0823"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"All affected males show moderate-severe intellectual disability (ID).  No statural growth deficiency, or minor facial or other abnormal physical features were observed.  Seizures present in one affected patient in the family.  Proband is individual IV-7; developmental quotient 25 at age 3 years.  Clinical assessment,\nincluding growth chart, hearing, vision and skin examination was normal. brain magnetic resonance imaging (MRI), electroencephalogram (EEG), biochemical blood and urine screening (thyroid-stimulating hormone, free thyroxine, amino acid chromatography) were normal.  Females III-9, III-11 and III-13 have a borderline intellectual functioning or a mild mental retardation and behavioural troubles with psychiatric features and social difficulties.","phenotypes":["obo:HP_0000750","obo:HP_0001252","obo:HP_0001249","obo:HP_0000733"],"previousTesting":true,"previousTestingDescription":"Negative for Fragile X.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/c32b5768-9709-44e7-ada4-f835921e384b_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"All affected males show moderate-severe intellectual disability (ID).  No statural growth deficiency, or minor facial or other abnormal physical features were observed.  Seizures present in one affected patient in the family.  Proband is individual IV-7; developmental quotient 25 at age 3 years.  Clinical assessment,\nincluding growth chart, hearing, vision and skin examination was normal. brain magnetic resonance imaging (MRI), electroencephalogram (EEG), biochemical blood and urine screening (thyroid-stimulating hormone, free thyroxine, amino acid chromatography) were normal.  Females III-9, III-11 and III-13 have a borderline intellectual functioning or a mild mental retardation and behavioural troubles with psychiatric features and social difficulties.","phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0001252","obo:HP_0001249","obo:HP_0000750","obo:HP_0000733"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/b0406c48-a281-4207-984f-56121342fa27"},"publishedLodScore":3.01,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/cb396500-049f-4d9f-a6fc-3d0c3d44b495_proband_segregation","type":"FamilyCosegregation","dc:description":"D'Adamo et al. state that \"affected and nonaffected relatives and obligate carriers were analysed and the mutations were shown to segregate with the disease,\" but they do not specify which individuals were actually tested.  The number of affected individuals in the pedigree in Hamel et al. is 8, with at least 3 obligate carriers.  Hamel et al. (PMID:8826463) performed \"[t]wo point linkage analysis demonstrat[ing] linkage between the disorder and marker DXS3 in Xq21.33 with a lod score of 2.56 at theta = 0.0 and marker DXSllO8 in Xq28 with a lod score of 3.82 at theta = 0.0.\"  Using the estimated LOD score calculation and assuming all affected individuals and obligate carriers were tested and found to carry the variant, the estimated LOD score could be up to 3.  Opting to use the more conservative LOD score published in Hamel due to the ambiguity of the information published in this paper (D'Adamo et al. 1998).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620768","rdfs:label":"D'Adamo 1998 Family MRX41","family":{"id":"https://genegraph.clinicalgenome.org/r/cb396500-049f-4d9f-a6fc-3d0c3d44b495","type":"Family","rdfs:label":"D'Adamo 1998 Family MRX41","member":{"id":"https://genegraph.clinicalgenome.org/r/14354b11-87ed-49c9-ac72-6c013f1782f9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620768","rdfs:label":"D'Adamo MRX41 Proband","allele":{"id":"https://genegraph.clinicalgenome.org/r/895f3f67-c732-43d6-a57b-e162d54f02b4"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"This family is described in Hamel et al. 1996 (PMID:8826463); a pedigree can be found in this publication.  Intellectual disability (ID) was mild-moderate, non-progressive and evident in the first years of life.  Per the authors of that study: \"None of the\naffected males is institutionalized, but all attended special schools for children with (severe) learning problems. They all live and work in a sheltered environment. There was no consistent clinical phenotype other than the mental retardation. Obvious neurological symptoms and signs were not present. Height, weight, and OFC were all within normal limits. Their behaviour is unremarkable.\"  All obligate and possible carriers were said to be of normal intelligence.  No particular individual is designated as the proband.","phenotypes":"obo:HP_0001249","previousTesting":true,"previousTestingDescription":"Cytogenetic analysis and FMR1 testing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/dd79d3ee-7c6d-4539-8da6-14b2da391a9c_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"This family is described in Hamel et al. 1996 (PMID:8826463); a pedigree can be found in this publication.  Intellectual disability (ID) was mild-moderate, non-progressive and evident in the first years of life.  Per the authors of that study: \"None of the\naffected males is institutionalized, but all attended special schools for children with (severe) learning problems. They all live and work in a sheltered environment. There was no consistent clinical phenotype other than the mental retardation. Obvious neurological symptoms and signs were not present. Height, weight, and OFC were all within normal limits. Their behaviour is unremarkable.\"  All obligate and possible carriers were said to be of normal intelligence.","phenotypePositiveAllelePositive":8,"phenotypes":"obo:HP_0001249","proband":{"id":"https://genegraph.clinicalgenome.org/r/14354b11-87ed-49c9-ac72-6c013f1782f9"},"publishedLodScore":2.56,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/6319daaa-db2e-4659-8934-f11f775dbf10_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28863211","rdfs:label":"Duan 2017 SZMRX Family","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/6319daaa-db2e-4659-8934-f11f775dbf10","type":"Family","rdfs:label":"Duan 2017 SZMRX Family","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/ce9779b2-e2a1-4cd4-ab9b-86ce197fa4cc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28863211","rdfs:label":"Duan 2017 Proband 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e9e618c0-073e-4982-820f-db965b4ae34e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001493.3(GDI1):c.710G>T (p.Gly237Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1303709"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","previousTesting":true,"previousTestingDescription":"G-banding Karyotype and Fragile X analysis","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/9006bb0f-0e43-4b09-b352-cd78f89a4996_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28863211","allele":{"id":"https://genegraph.clinicalgenome.org/r/e9e618c0-073e-4982-820f-db965b4ae34e"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":3,"phenotypes":"obo:HP_0001249","proband":{"id":"https://genegraph.clinicalgenome.org/r/ce9779b2-e2a1-4cd4-ab9b-86ce197fa4cc"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/f13b920a-fcce-4133-a04b-24d8ffafcaae","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f13b920a-fcce-4133-a04b-24d8ffafcaae_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/9006bb0f-0e43-4b09-b352-cd78f89a4996","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9006bb0f-0e43-4b09-b352-cd78f89a4996_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":5.8}],"evidenceStrength":"Moderate","sequence":10957,"specifiedBy":"GeneValidityCriteria10","strengthScore":11.3,"subject":{"id":"https://genegraph.clinicalgenome.org/r/20s_eD13bEk","type":"GeneValidityProposition","disease":"obo:MONDO_0019181","gene":"hgnc:4226","modeOfInheritance":"obo:HP_0001417"},"version":"2.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_8afc42b0-6c5e-460b-87d1-035c051fe7ca-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}